A Comprehensive Strategy for the Interpretation of Quality-of-Life Data Based on Existing Methods

Value in Health

Volumn 7, Issue 1, 2004, Pages 93-104

  Marquis, Patrick ^a   Chassany, Olivier ^b   Abetz, Linda ^a  

^a MAPI VALUES   (United States)

^b HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Clinical significance; Comprehensive strategy; Interpretation; Quality of life

Indexed keywords

HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; REFERENCE VALUE; REPRODUCIBILITY; REVIEW; SCORING SYSTEM; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 0442309290     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2004.71217.x     Document Type: Article

References (73)

1. Wood-Dauphinee S. Assessing quality of life in clinical research: from where have we come and where are we going? J Clin Epidemiol 1999; 52:355-63.
2. Saunders C, Egger M, Donovan J, et al. Reporting on quality of life in randomised controlled trials: bibliographic study. BMJ 1998;317:1191-4.
3. Chassany O, Sagnier P, Marquis P, et al. Patient-reported outcomes, the example of health-related quality of life - a European guidance document for the improved integration of health-related quality of life assessment in the drug regulatory process. Drug Inf J 2002;36:1-10.
4. Herrmann C. International experiences with the Hospital Anxiety and Depression Scale: a review of validation data and clinical results. J Psychosom Res 1997;42:17-41.
5. Streiner DL, Norman GR. Health Measurement Scales. A Practical Guide to Their Development and Use. New York: Oxford University Press, 1989.
6. MOS Instrument Review Criteria. Med Outcomes Trust Bull, September, 1995;3:I-IV.
7. Lydick E, Epstein RS. Interpretation of quality of life changes. Qual Life Res 1993;2:221-6.
8. Jaeschke R, Singer J, Guyatt GH. Measurement of health status: ascertaining the minimal clinically important difference. Control Clin Trials 1989;10: 407-15.
9. Erickson P, Scott J. The On-Line Guide to Quality-of-Life Assessment (OLGA): resource for selecting quality of life assessments. In: Walker S, Rosser RM, eds., Quality of Life Assessment: Key Issues in the 1990s. Dordrecht: Kluwer Acedemic, 1993.
10. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993;11:570-9.
11. Aaronson NK, Ahmedzai S, Bergmen B, et al. The European Organisation for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85: 365-76.
12. Keinanen-Kiukaanniemi S, Ohinmaa A, Pajunpaa H, et al. Health-related quality of life in diabetic patients measured by the Nottingham Health Profile. Diabet Med 1996;13:382-8.
13. Anderson RM, Fitzgerald JT, Wisdom K, et al. A comparison of global versus disease-specific quality of life measures in patients with NIDDM. Diabetes Care 1997;20:299-305.
14. Sprangers MAG, Moinpour CM, Moynihan TJ, et al. Assessing meaningful change in quality of life over time: a users' guide for clinicians. Mayo Clin Proc 2002;77:561-71.
15. Fayers P, Machin D. Missing data. In: Fayers PM, ed., Quality of Life: Assessment, Analysis, and Interpretation. West Sussex: Wiley, 2000. p. 224-46.
16. Fayers P, Curran D, Machin D. Incomplete quality of life data in randomized trials: missing items. Stat Med 1998;17:679-96.
17. Fairclough D, Cella D. Functional assessment of cancer therapy (FACT-G): non-response to individual questions. Qual Life Res 1996;5:321-9.
18. Ware JE. Interpreting general health measures. In: Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. 2nd ed. Philadelphia: Lippincott-Raven, 1996.
19. Deyo RA, Diehr P, Patrick DL. Reproducibility and responsiveness of health status measures, statistics and strategies for evaluation. Control Clin Trials 1991;12(Suppl):S142-58.
20. Acquadro C, Jambon B, Ellis D, Marquis P. Language and translation issues. In: Spilker B, ed., Quality of Life and Pharmaco-Economics in Clinical Trials. 2nd ed. Philadelphia: Lippincott-Raven, 1995.
21. Guillemin F, Bombardier C, Beaton DE. Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines. J Clin Epidemiol 1994;47:1465-6.
22. Bullinger M, Alonso J, Apolone G, et al. Translating health status questionnaires and evaluating their quality: the IQOLA Project approach-international quality of life assessment. J Clin Epidemiol 1998;51:913-23.
23. Boyle P. Cultural and linguistic validation of questionnaires for use in international studies: the nine-item BPH-specific quality of life scale. Eur Urol 1997;32(Suppl 2):S50-2.
24. Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care 1989;27:178-89.
25. King MT. The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res 1996;5:555-67.
26. Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998;16:139-44.
27. Ware JE, Snow KK, Kosinski M, et al. SF-36 Health Survey: manual and interpretation guide. Boston: New England Medical Center, The Health Institute, 1993.
28. Nunnally JC, Bernstein IR. Psychometric Theory Boston. 3rd ed. New York: McGraw-Hill, 1994.
29. Ware JE, Kosinski M, Keller SD. SF-36 physical and mental component summary measures - a user's manual. Boston: The Health Institute, 1994.
30. Brazier JE, Harper R, Jones NMB, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 1992;305: 160-4.
31. Bergner L, Bergner M, Hallstrom AP, et al. Health status of survivors of out-of-hospital cardiac arrest six months later. Am J Public Health 1984;74: 508-10.
32. Hunt SM, McKenna SP, Williams J, et al. The Nottingham Health Profile: subjective health status and medical consultations. Soc Sci Med 1981;15a: 221-9.
33. Testa MA, Anderson RB, Nackley JF, et al. Quality of life and antihypertensive therapy in men: a comparison of captopril with enalapril. The Quality of Life Hypertension Study Group. N Engl J Med 1993;328:907-13.
34. Jaeschke R, Guyatt GH, Keller J, et al. Ascertaining the meaning of change in quality of life questionnaire score: data from N of 1 randomized control trials. Control Clin Trials 1991;12(Suppl): S226-33.
35. Guyatt GH, Berman LB, Townsend M, et al. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987;42:773-8.
36. Guyatt GH, Nogradi S, Halcrow S, et al. Development and testing of a new measure of health status for clinical trials in heart failure. J Gen Intern Med 1989;4:101-7.
37. Juniper EF, Guyatt GH, Epstein RS, et al. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 1992;47:76-83.
38. Juniper EF, Guyatt GH, Willan A, et al. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 1994;47:81-7.
39. Jaeschke R, Guyatt GH, Keller J, et al. Ascertaining the meaning of change in quality of life questionnaire score: data from N of 1 randomized control trials. Control Clin Trials 1991;12(Suppl): S226-33.
40. Anderson RB. What does it mean? Anchoring psychosocial quality of life scale score changes with reference to concurrent changes on reported symptom distress. Drug Inf J 1999;33:445-53.
41. Wyrwich KW, Nienaber NA, Tierney W, et al. Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. Med Care 1999;37: 469-78.
42. Wyrwich KW, Tierney WM, Wolinsky FE. Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health related quality of life. J Clin Epidemiol 1999;52:861-73.
43. Barry MJ, Fowler FJ, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 1992;148: 1549-57.
44. Barry MJ, Williford WO, Chang Y, et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol 1995;154:1770-4.
45. Arocho R, McMillan CA, Sutton-Wallace P. Construct validation of the USA-Spanish version of the SF-36 Health Survey in a Cuban-American population with benign prostatic hyperplasia. Qual Life Res 1998;7:121-6.
46. McHorney CA, Kosinski M, Ware JE Jr. Comparisons of the costs and quality of norms for the SF-36 health survey collected by mail versus telephone interview: results from a national survey. Med Care 1994;32:551-67.
47. Gandek B, Ware JE. Translating functional health and well-being: international quality of life assessment (IQOLA) project studies of the SF-36 health survey. J Clin Epidemiol 1998;51:891-1214.
48. Lewin-Epstein N, Sagiv-Schifter T, Shabtai EL, Shmueli A. Validation of the 36-item short-form health survey (Hebrew version) in the adult population of Israel. Med Care 1998;36:1361-70.
49. Loge JH, Kaasa S. Short form 36 (SF-36) health survey: normative data from the general Norwegian population. Scand J Soc Med 1998;26:250-8.
50. Prieto L, Alonso J, Ferrer M, et al. Are results of the SF-36 health survey and the Nottingham Health Profile similar? A comparison in COPD patients. Quality of Life in COPD Study Group. J Clin Epidemiol 1997;50:463-73.
51. Bronfort G, Bouter LM. Responsiveness of general health status in chronic low pain: a comparison of the COOP charts and the SF-36. Pain 1999;83: 201-9.
52. Damiano AM. The Sickness Impact Profile: User's Manual and Interpretation Guide. Medical Outcomes Trust, Boston MA. Baltimore (MD): The Johns Hopkins University, 1996.
53. Stucki G, Liang MH, Fossel AH, et al. Relative responsiveness of condition-specific and generic health status measures in degenerative lumbar spinal stenosis. J Clin Epidemiol 1995;48:1369-78.
54. The European Group for Quality of Life and Health Measurement. European Guide to the Nottingham Health Profile. The European Group for Quality of Life and Health Measurement (eds). 1992.
55. Hjermstad MJ, Fayers PM, Bjordal K, et al. Health related quality of life in the Norwegian general population assessed by the European Organisation for Research and Treatment of Cancer core quality of life questionnaire: the QLQ-C30(+3). J Clin Oncol 1998;16:1188-96.
56. Klee M, Groenvold M, Machin D. Quality of life of Danish women: population-based norms of the EORTC QLQ-C30. Qual Life Res 1997;6: 27-34.
57. Groenvold M, Klee MC, Sprangers MA, et al. Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient-observer agreement. J Clin Epidemiol 1997;50:441-50.
58. Overcash J, Extermann M, Parr J, et al. Validity and reliability of the FACT-G scale for use in the older person with cancer. Am J Clin Oncol 2001;24:591-6.
59. Cella D, Hahn EA, Dineen K. Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening. Qual Life Res 2002;11:207-21.
60. Cella D. Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System. Evanston (IL): Evanston Northwestern Healthcare and Northwestern University, 1997.
61. Cella D, Eton DT, Fairclough DL, et al. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol 2002;55:285-95.
62. Barber BL, Santanello NC, Epstein RS. Impact of the global on patient perceivable change in an asthma specific QoL questionnaire. Qual Life Res 1996;5:117-22.
63. Samsa G, Edelman D, Rothman M, et al. Determining clinically important differences in health status measures. Pharmacoeconomics 1999;15: 141-55.
64. Wright JG. The minimal important difference: who's to say what is important? J Clin Epidemiol 1996;49:1221-2.
65. Norman GR, Stratford P, Regehr G. Methodological problems in the retrospective computation of responsiveness to change: the lessons of Cronbach. J Clin Epidemiol 1997;50:869.
66. Hays RD, Woolley JM. The concepts of clinically meaningful difference in health-related quality-of-life research: how meaningful is it? Pharmacoeconomics 2000;18:419-23.
67. Donald P, Gagnon D, Zagari M. Assessing the clinical significance of changes in health-related quality of life (HRQOL) scores. In: Abstract Issue 7th Annual Conference of the International Society of Qual Life Res 2000;9:275.
68. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med 1991;85(Suppl B):S25-31.
69. Wells GA, Tugwell P, Kraag GR, et al. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993;20:557-60.
70. Rose MS, Koshman ML, Spreng S, Sheldon R. Statistical issues encountered in the comparison of health-related quality of life in diseased patients to published general population norms: problems and solutions. J Clin Epidemiol 1999;52:405-12.
71. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988; 318:1728-33.
72. Guyatt GH, Juniper EF, Walter SD, et al. Interpreting treatment effects in randomised clinical trials. BMJ 1998;316:690-3.
73. Symonds T, Berzon R, Marquis P, et al. The clinical significance of quality-of-life results: practical considerations for specific audiences. Mayo Clinic Proc 2002;77:572-83.